Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE REGULATORY NEWS IN BRIEF
August 27, 2007
-
COMMENTARY COMMENTARY/NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
-
ARCHIVE Vice Health Minister Unofficially Meets JGPMA Leaders to Promote Use of Generics
August 27, 2007
-
ARCHIVE Antidepressant Medication Altered by 40% of Patients: GSK
August 27, 2007
-
ARCHIVE 47 Programs in PII Trials: Pfizer
August 27, 2007
-
ARCHIVE Ono Licenses General Anesthetic from CeNeS
August 27, 2007
-
ARCHIVE 3 Ministries Discuss How to Develop Ventures
August 27, 2007
-
ARCHIVE Hisamitsu Licenses for Percutaneous Pain Killer from Mundipharma
August 27, 2007
-
ARCHIVE R&D NEWS IN BRIEF
August 27, 2007
-
ARCHIVE Toho Pharm., Ohki, and Kokubu to Tie Up
August 27, 2007
-
ARCHIVE OPINION/Our Attitude Leads to Our Altitude
August 27, 2007
-
ARCHIVE Korosho Presents "Emergency Proposals" to Improve Business Practices
August 27, 2007
-
ARCHIVE Industry, Gov't, Academia to Jointly Develop New Medical Devices
August 27, 2007
-
ARCHIVE Discussion on Copyright on Literature Resumed
August 27, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
August 27, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
August 27, 2007
-
ARCHIVE MOF Demands \220 Bil. Cut in Social Security Spending Again in FY2008
August 27, 2007
-
ARCHIVE Chuikyo to Show Road Map for Revisions of Medical Fees in April 2008
August 27, 2007
-
ARCHIVE SEMINAR
August 27, 2007
-
ARCHIVE Korosho Starts Studies for Mutual Acceptance of Clinical Data from Japan, Korea, China
August 27, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…